LifeMD Analyst Ratings
Lake Street Initiates LifeMD(LFMD.US) With Buy Rating, Announces Target Price $12
Mizuho Initiates Coverage On LifeMD With Neutral Rating, Announces Price Target of $7
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
H.C. Wainwright Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12
LifeMD Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
LifeMD Analyst Ratings
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating, Announces Target Price $16
B.Riley Financial Maintains LifeMD(LFMD.US) With Buy Rating, Raises Target Price to $12
B. Riley Adjusts Price Target on LifeMD to $12 From $11, Maintains Buy Rating
BTIG Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12
B.Riley Financial Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $11
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
Craig-Hallum Keeps Their Buy Rating on LifeMD (LFMD)
B.Riley Financial Maintains LifeMD(LFMD.US) With Buy Rating, Cuts Target Price to $11
LifeMD Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on LifeMD, Maintains $15 Price Target
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA) and LifeMD (LFMD)